Search

In summary, this international registry showed a rather stable disease activity in the majority of AIBD patients following COVID-19 infection. Death occurred in nine patients (13%) with a mean age of 84.3 years; 6 of the 9 patients (67%) of them died during hospitalization for COVID-19 infection. Respectively, the change in disease activity of AIBD before and after COVID-19 infection is shown in Figure 1d. 1 TABLE Reported systemic treatment for AIBD before and after COVID-19 infection. [Extracted from the article]

Background/purpose: Using a new eosinophil isolation kit, we were not able to confirm our previous findings of a delayed apoptosis of eosinophils in atopic dermatitis. Thus, we investigated whether this new isolation kit modulates the functional activity of eosinophils. Methods: Peripheral blood eosinophils were isolated with the new isolation kit as well as conventionally with anti-CD16-conjugated MicroBeads. We analysed viability, apoptosis, CD69 and CD95 expression, streptavidin binding and superoxide anion release. Results: Purity of eosinophils was higher using the new isolation kit ( P < 0.05). However, these eosinophils had a decreased survival ( P < 0.05–0.01), presented morphological features of apoptosis, showed an increased percentage of apoptotic nuclei ( P < 0.01), an increased release of superoxide anions ( P < 0.05), a higher expression of CD69 and CD95 ( P < 0.05) and an increased binding to streptavidin compared to eosinophils isolated with anti-CD16 conjugated MicroBeads. Conclusion: The new eosinophil isolation kit should not be used for the investigation of eosinophils as it potently affects their functional activity. [ABSTRACT FROM AUTHOR]